Accueil Ernstrade Bourse Actualite Stock


Exchanges: Germany

Formycon is a leading, independent developer of high-quality follow-on products for biopharmaceutical medicines known as biosimilars. The company focuses on ophthalmology treatments and on other key chronic diseases, covering the entire added value chain from technical development to the clinical phase III and approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development, two of which have already been licensed out.

Copyright  2017